The effect of gabapentin and the combination of gabapentin and montelukast on cough in Covid-19 patients

Evaluation of the effectiveness of gabapentin and montelukast + gabapentin combination compared to dextromethorphan in the improvement of cough in patients with COVID-19 pneumonia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N24

Enrollment

185

Registered

2022-12-21

Start date

2022-06-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: gabapentin 300-mg Capsules , every 8 hours, for 6 days. Intervention 2: Intervention group: gabapentin 300-mg Capsules+ montelukast 10-mg, every 8 hours, for 6 days

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Infection of Covid-19 with any severity with the criteria of pulmonary involvement in lung CT scan with positive test RT PCR Covid-19 BCSS score higher than 2 Oral intake (PO) tolerance

Exclusion criteria

Exclusion criteria: mechanical ventilation Allergy to drugs Loss of consciousness discharge earlier than 6 days Chronic underlying and allergic lung disease

Design outcomes

Primary

Measure	Time frame
Cough severity. Timepoint: Before and after the intervention. Method of measurement: VAS (Visual analog scale).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir+98 31 3786 5537

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026